Utilizing CD44v6 and V600EBRAF-mutation for in vitro targeted combination therapy of thyroid carcinomas.
利用 CD44v6 和 V600EBRAF 突变进行甲状腺癌的体外靶向联合治疗
期刊:Heliyon
影响因子:3.6
doi:10.1016/j.heliyon.2023.e22594
Mortensen A C L, Imgenberg-Kreuz J, Spiegelberg D, Botling J, Nestor M
